Company:  GALENA BIOPHARMA, INC. (GALE)
Form Type:  8-K
Filing Date:  11/18/2011 
CIK:  0001390478 
Address:  4640 SW MACADAM AVENUE
SUITE 270
 
City, State, Zip:  PORTLAND, Oregon 97239 
Telephone:  855 855 GALE 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.34  
Change: 
-0.003 (-0.96%)  
Trade Time: 
Aug 18  
Market Cap: 
$13.06M
Trade GALE now with 

© 2017  
Description of Business
Galena Biopharma, Inc. ("we," "us," "our," "Galena" or the "Company") is a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs. The Company's pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, and our novel cancer immunotherapy programs including NeuVax(TM) (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE- 401 has completed a Phase 2 clinical trial and the asset is ready to advance into a pivotal trial in patients with essential thrombocythemia (ET). NeuVax is currently in multiple investigator-sponsored Phase 2 clinical trials in breast cancer. GALE-301 and GALE-302 have completed early stage trials in ovarian, endometrial and breast cancers.
Register and access this filing in:     
  FORM 8-K
    SECTION 3 SECURITIES AND TRADING MARKETS
      Item 3.01 Notice of Delisting or Failure to Satisfy a ...
    SIGNATURES